NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

NeuroOne Medical Technologies Corp excels in Q2 2024 performance

NeuroOne Medical Technologies Corp demonstrated strong commercial and financial performance in Q2 2024.
The company's focus on innovation, strategic partnerships, and diverse product development is driving growth.
While facing challenges in capital management and market competition, NeuroOne is well-positioned for future success.
Opportunities in product diversification, market expansion, and fundraising set the stage for continued growth and profitability.

NeuroOne Medical Technologies Corp reports strong Q3 performance and expansion opportunities

NMTC's Q3 2024 performance reflects progress in commercialization and product revenue growth, supported by strategic financing initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to capitalize on distribution agreements and product expansion.
With a focus on innovation and market penetration, NMTC is poised for growth through new FDA applications and leveraging its technological advancements.

NeuroOne Medical Technologies Corp achieves FDA clearance and revenue growth

NeuroOne Medical Technologies Corp made significant strides in product development, securing partnerships, and achieving FDA clearance, positioning the company for growth.
While facing challenges in stock price compliance and market competition, the company's focus on innovation and revenue growth presents opportunities for expansion.
With a strong financial performance in 2024 and revenue growth projections for 2025, NeuroOne is poised to capitalize on market demand and technological advancements.
By diversifying product applications and exploring new partnerships, NeuroOne aims to drive market penetration and establish itself as a key player in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the first quarter fiscal year 2024 ended December 31, 2023.

NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on February 13, 2024 at 4:30 PM Eastern Time to discuss financial results for its first quarter of fiscal year 2024 ended December 31, 2023, and provide a corporate update.

NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q4 2023 Results Conference Call December 14, 2023 5:00 PM ET Company Participants Dave Rosa - CEO Ron McClurg - CFO Conference Call Participants Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by, and welcome to the NeuroOne Medical Technologies Corporation Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa, and Chief Financial Officer, Ron McClurg.

NeuroOne Medical Technologies Corporation (NMTC) Q4 2023 Earnings Call Transcript

EDEN PRAIRIE, Minn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal fourth quarter and full fiscal year ended September 30, 2023.

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Dec. 07, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fourth quarter and fiscal year ended September 30, 2023, and provide a corporate update, on December 14, 2023 at 5:00 PM Eastern Time.

NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14

Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes

NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe

Volker strengthens existing management team in areas of commercialization, business development, and reimbursement

NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Clearpoint Neuro Inc

Both NeuroOne and ClearPoint Neuro are emerging as significant players in the neurological device sector, each carving out their own niche, with ClearPoint focusing on drug delivery and NeuroOne advancing. NeuroOne is rapidly positioning itself as a formidable competitor in the brain drug delivery market, a niche where ClearPoint Neuro has established a strong foothold, indicating a potential shift. NeuroOne's ongoing strategic initiatives, including partnerships and product development, coupled with its improving financial health, present it as an attractive investment opportunity.

NeuroOne: A Hidden Contender Against ClearPoint In The Brain Drug Delivery Arena

EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the ThinkEquity Conference in New York on Thursday, October 19, 2023.

NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023

EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual presentation at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q3 2023 Results Conference Call August 14, 2023 4:30 PM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Operator Good day, ladies and gentlemen. Thank you for standing by.

NeuroOne Medical Technologies Corporation (NMTC) Q3 2023 Earnings Call Transcript

EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal third quarter 2023 ended June 30, 2023.

NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time.

NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14

EDEN PRAIRIE, Minn., July 24, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

Potential for tran s formative improvement in neurosurgery as f irst known sEEG -guided RF system that records and ablates nervous tissue with the added benefit of temperature control

NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System

Evo sEEG electrode used with Zimmer Biomet 's ROSA One ® Brain during procedure at Cleveland Clinic

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q2 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Second Quarter Fiscal Year 2023 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q2 2023 Earnings Call Transcript

EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal second quarter 2023 ended March 31, 2023.

NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal second quarter 2023 ended March 31, 2023 and provide a corporate update on May 11, 2023 at 4:30 PM Eastern Time.

NeuroOne® to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11

Evo sEEG electrode s used for brain mapping in epilepsy surgery

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic

EDEN PRAIRIE, Minn., May 05, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the Sidoti Micro-Cap Virtual Conference being held May 10-11, 2023.

NeuroOne® to Present at the Sidoti Micro-Cap Virtual Conference on May 10

Evo sEEGs complementary to Zimmer Biomet's robotic neurosurgery platform; strong market opportunity for paired technologies

NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes

Company is also developing a percutaneous (through a needle) delivery system for paddle leads EDEN PRAIRIE, Minn. , March 16, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the successful completion of an initial animal implant of its novel thin film paddle leads for spinal cord stimulation.

NeuroOne® Successfully Completes Initial Animal Implant of Novel Thin Film Paddle Lead for Spinal Cord Stimulation

EDEN PRAIRIE, Minn. , March 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California.

NeuroOne®#¹⁶⁰;to Participate in the 35th Annual Roth Conference

New patent adds value to NeuroOne's growing patent portfolio in the U.S. and abroad EDEN PRAIRIE, Minn. , March 7, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces it has been awarded a patent from the United States Patent and Trademark Office relating to its novel and proprietary electrode technology.

News for NeuroOne Medical Technologies Corp Stock (NMTC)